MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma
Summary Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients r...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1990 |
|---|
| Umfang: |
5 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Annals of hematology - 1955, 60(1990) vom: Jan., Seite 23-27 |
| Übergeordnetes Werk: |
volume:60 ; year:1990 ; month:01 ; pages:23-27 ; extent:5 |
| Links: |
|---|
| Katalog-ID: |
NLEJ202967662 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ202967662 | ||
| 003 | DE-627 | ||
| 005 | 20230505233625.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1990 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ202967662 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma |
| 264 | 1 | |c 1990 | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Oster, W. |4 oth | |
| 700 | 1 | |a Forsthuber, T. |4 oth | |
| 700 | 1 | |a Hennekeuser, H. H. |4 oth | |
| 700 | 1 | |a Gamm, H. |4 oth | |
| 700 | 1 | |a Lindemann, A. |4 oth | |
| 700 | 1 | |a Schmitz, G. |4 oth | |
| 700 | 1 | |a Fuhr, H. -G. |4 oth | |
| 700 | 1 | |a Hinterberger, R. |4 oth | |
| 700 | 1 | |a Kreiter, H. |4 oth | |
| 700 | 1 | |a Thoenes, W. |4 oth | |
| 700 | 1 | |a Herrmann, F. |4 oth | |
| 700 | 1 | |a Mertelsmann, R. |4 oth | |
| 773 | 0 | 8 | |i in |t Annals of hematology |d 1955 |g 60(1990) vom: Jan., Seite 23-27 |w (DE-627)NLEJ18898836X |w (DE-600)1458429-3 |x 1432-0584 |7 nnns |
| 773 | 1 | 8 | |g volume:60 |g year:1990 |g month:01 |g pages:23-27 |g extent:5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF01720198 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 60 |j 1990 |c 1 |h 23-27 |g 5 | ||
| matchkey_str |
article:14320584:1990----::aobhmteayoteramnohggaenitreitg |
|---|---|
| hierarchy_sort_str |
1990 |
| publishDate |
1990 |
| allfields |
(DE-627)NLEJ202967662 DE-627 ger DE-627 rakwb eng MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma 1990 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL. Springer Online Journal Archives 1860-2002 Oster, W. oth Forsthuber, T. oth Hennekeuser, H. H. oth Gamm, H. oth Lindemann, A. oth Schmitz, G. oth Fuhr, H. -G. oth Hinterberger, R. oth Kreiter, H. oth Thoenes, W. oth Herrmann, F. oth Mertelsmann, R. oth in Annals of hematology 1955 60(1990) vom: Jan., Seite 23-27 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:60 year:1990 month:01 pages:23-27 extent:5 http://dx.doi.org/10.1007/BF01720198 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 60 1990 1 23-27 5 |
| spelling |
(DE-627)NLEJ202967662 DE-627 ger DE-627 rakwb eng MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma 1990 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL. Springer Online Journal Archives 1860-2002 Oster, W. oth Forsthuber, T. oth Hennekeuser, H. H. oth Gamm, H. oth Lindemann, A. oth Schmitz, G. oth Fuhr, H. -G. oth Hinterberger, R. oth Kreiter, H. oth Thoenes, W. oth Herrmann, F. oth Mertelsmann, R. oth in Annals of hematology 1955 60(1990) vom: Jan., Seite 23-27 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:60 year:1990 month:01 pages:23-27 extent:5 http://dx.doi.org/10.1007/BF01720198 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 60 1990 1 23-27 5 |
| allfields_unstemmed |
(DE-627)NLEJ202967662 DE-627 ger DE-627 rakwb eng MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma 1990 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL. Springer Online Journal Archives 1860-2002 Oster, W. oth Forsthuber, T. oth Hennekeuser, H. H. oth Gamm, H. oth Lindemann, A. oth Schmitz, G. oth Fuhr, H. -G. oth Hinterberger, R. oth Kreiter, H. oth Thoenes, W. oth Herrmann, F. oth Mertelsmann, R. oth in Annals of hematology 1955 60(1990) vom: Jan., Seite 23-27 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:60 year:1990 month:01 pages:23-27 extent:5 http://dx.doi.org/10.1007/BF01720198 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 60 1990 1 23-27 5 |
| allfieldsGer |
(DE-627)NLEJ202967662 DE-627 ger DE-627 rakwb eng MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma 1990 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL. Springer Online Journal Archives 1860-2002 Oster, W. oth Forsthuber, T. oth Hennekeuser, H. H. oth Gamm, H. oth Lindemann, A. oth Schmitz, G. oth Fuhr, H. -G. oth Hinterberger, R. oth Kreiter, H. oth Thoenes, W. oth Herrmann, F. oth Mertelsmann, R. oth in Annals of hematology 1955 60(1990) vom: Jan., Seite 23-27 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:60 year:1990 month:01 pages:23-27 extent:5 http://dx.doi.org/10.1007/BF01720198 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 60 1990 1 23-27 5 |
| allfieldsSound |
(DE-627)NLEJ202967662 DE-627 ger DE-627 rakwb eng MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma 1990 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL. Springer Online Journal Archives 1860-2002 Oster, W. oth Forsthuber, T. oth Hennekeuser, H. H. oth Gamm, H. oth Lindemann, A. oth Schmitz, G. oth Fuhr, H. -G. oth Hinterberger, R. oth Kreiter, H. oth Thoenes, W. oth Herrmann, F. oth Mertelsmann, R. oth in Annals of hematology 1955 60(1990) vom: Jan., Seite 23-27 (DE-627)NLEJ18898836X (DE-600)1458429-3 1432-0584 nnns volume:60 year:1990 month:01 pages:23-27 extent:5 http://dx.doi.org/10.1007/BF01720198 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 60 1990 1 23-27 5 |
| language |
English |
| source |
in Annals of hematology 60(1990) vom: Jan., Seite 23-27 volume:60 year:1990 month:01 pages:23-27 extent:5 |
| sourceStr |
in Annals of hematology 60(1990) vom: Jan., Seite 23-27 volume:60 year:1990 month:01 pages:23-27 extent:5 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Annals of hematology |
| authorswithroles_txt_mv |
Oster, W. @@oth@@ Forsthuber, T. @@oth@@ Hennekeuser, H. H. @@oth@@ Gamm, H. @@oth@@ Lindemann, A. @@oth@@ Schmitz, G. @@oth@@ Fuhr, H. -G. @@oth@@ Hinterberger, R. @@oth@@ Kreiter, H. @@oth@@ Thoenes, W. @@oth@@ Herrmann, F. @@oth@@ Mertelsmann, R. @@oth@@ |
| publishDateDaySort_date |
1990-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ18898836X |
| id |
NLEJ202967662 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202967662</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505233625.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1990 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202967662</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1990</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oster, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Forsthuber, T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hennekeuser, H. H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gamm, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lindemann, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmitz, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fuhr, H. -G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hinterberger, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kreiter, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thoenes, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Herrmann, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mertelsmann, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annals of hematology</subfield><subfield code="d">1955</subfield><subfield code="g">60(1990) vom: Jan., Seite 23-27</subfield><subfield code="w">(DE-627)NLEJ18898836X</subfield><subfield code="w">(DE-600)1458429-3</subfield><subfield code="x">1432-0584</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:60</subfield><subfield code="g">year:1990</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:23-27</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01720198</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">60</subfield><subfield code="j">1990</subfield><subfield code="c">1</subfield><subfield code="h">23-27</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ18898836X |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-0584 |
| topic_title |
MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
w o wo t f tf h h h hh hhh h g hg a l al g s gs h - f h- h-f r h rh h k hk w t wt f h fh r m rm |
| hierarchy_parent_title |
Annals of hematology |
| hierarchy_parent_id |
NLEJ18898836X |
| hierarchy_top_title |
Annals of hematology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ18898836X (DE-600)1458429-3 |
| title |
MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma |
| spellingShingle |
MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma |
| ctrlnum |
(DE-627)NLEJ202967662 |
| title_full |
MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma |
| journal |
Annals of hematology |
| journalStr |
Annals of hematology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1990 |
| contenttype_str_mv |
zzz |
| container_start_page |
23 |
| container_volume |
60 |
| physical |
5 |
| format_se |
Elektronische Aufsätze |
| title_sort |
macop-b chemotherapy for the treatment of high grade and intermediate grade non hodgkin's lymphoma |
| title_auth |
MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma |
| abstract |
Summary Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL. |
| abstractGer |
Summary Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL. |
| abstract_unstemmed |
Summary Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma |
| url |
http://dx.doi.org/10.1007/BF01720198 |
| remote_bool |
true |
| author2 |
Oster, W. Forsthuber, T. Hennekeuser, H. H. Gamm, H. Lindemann, A. Schmitz, G. Fuhr, H. -G. Hinterberger, R. Kreiter, H. Thoenes, W. Herrmann, F. Mertelsmann, R. |
| author2Str |
Oster, W. Forsthuber, T. Hennekeuser, H. H. Gamm, H. Lindemann, A. Schmitz, G. Fuhr, H. -G. Hinterberger, R. Kreiter, H. Thoenes, W. Herrmann, F. Mertelsmann, R. |
| ppnlink |
NLEJ18898836X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth |
| up_date |
2024-07-06T09:24:15.843Z |
| _version_ |
1803821101448429569 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ202967662</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505233625.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1990 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ202967662</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1990</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doborubicin, cyclophosphamide, vincristine, prednison and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group with relapsed disease 14% had PR and 14% had progressive disease (PD). At a medium follow-up of 12 months (range 1 month to 33 months), 74% of patients with de novo NHL continued to be in CR whereas the continuous CR rate in patients with relapsed disease was 35%. Overall survival after 30 months of observation for the patient group with de novo NHL was 75% and 40% for patients with relapsed NHL. The mean duration for completion of the projected 12 chemotherapy cycles, given in weekly intervals, was 12.9 and 13.5 weeks in upfront or salvage therapy, respectively. With low incidence of major toxicities, application of drugs on an outpatient basis, and high efficacy, MACOP-B shows substantial advantges for therapy of de novo and relapsed NHL.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oster, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Forsthuber, T.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hennekeuser, H. H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gamm, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lindemann, A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmitz, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fuhr, H. -G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hinterberger, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kreiter, H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Thoenes, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Herrmann, F.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mertelsmann, R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Annals of hematology</subfield><subfield code="d">1955</subfield><subfield code="g">60(1990) vom: Jan., Seite 23-27</subfield><subfield code="w">(DE-627)NLEJ18898836X</subfield><subfield code="w">(DE-600)1458429-3</subfield><subfield code="x">1432-0584</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:60</subfield><subfield code="g">year:1990</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:23-27</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF01720198</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">60</subfield><subfield code="j">1990</subfield><subfield code="c">1</subfield><subfield code="h">23-27</subfield><subfield code="g">5</subfield></datafield></record></collection>
|
| score |
7.400093 |